Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6767-6772

  Lewis, Russell E ^a   Albert, Nathaniel D ^b   Kontoyiannis, Dimitrios P ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEFERASIROX; DEFEROXAMINE; POSACONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BENZOIC ACID DERIVATIVE; ECHINOCANDIN; TRIAZOLE DERIVATIVE;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; ELIMINATION HALF-LIFE; FEMALE; FUNGAL STRAIN; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; MOUSE; MUCORMYCOSIS; NEUTROPENIA; NONHUMAN; PARALLEL DESIGN; PLASMA CONCENTRATION-TIME CURVE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RHIZOPUS ORYZAE; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; ASPERGILLOSIS; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; INVASIVE PULMONARY ASPERGILLOSIS; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RHIZOPUS;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BENZOATES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; INVASIVE PULMONARY ASPERGILLOSIS; LUNG; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUCORMYCOSIS; NEUTROPENIA; RHIZOPUS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84908577004     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03569-14     Document Type: Article

References (33)

1. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, Mcnicholas PM. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome p450 14 alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574. http://dx.doi.org/10.1128/AAC .48.2.568-574.2004.
2. Chau AS, Chen G, Mcnicholas PM, Mann PA. 2006. Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae. Antimicrob. Agents Chemother. 50:3917-3919. http://dx.doi.org/10.1128/AAC.00747-06.
3. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. 2002. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46:2310-2312. http://dx.doi.org/10.1128/AAC.46.7.2310-2312.2002.
4. Dannaoui E, Meletiadis J, Mouton JW, Meis J, Verweij PE. 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51:45-52. http://dx.doi.org/10.1093/jac/dkg020.
5. Rodríguez MM, Pastor FJ, Calvo E, Salas V, Sutton DA, Guarro J. 2009. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob. Agents Chemother. 53:5022-5025. http://dx.doi.org/10.1128/AAC.01026-09.
6. Salas V, Pastor FJ, Rodriguez MM, Calvo E, Mayayo E, Guarro J. 2011. In vitro activity and in vivo efficacy of posaconazole in treatment of murine infections by different isolates of the Aspergillus terreus complex. Antimicrob. Agents Chemother. 55:676-679. http://dx.doi.org/10.1128/AAC .00736-10.
7. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:e61-e65. http://dx.doi.org/10.1086/500212.
8. Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiberger T, Guinea J, Guarro J, De Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Florl C, Lortholary O, Meis JF, Meletiadis J, Munoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, Van Diepeningen A, Verweij P, Petrikkos G. 2014. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin. Microbiol. Infect. 20(Suppl):5-26. http://dx.doi.org/10.1111/1469-0691.12371.
9. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666. http://dx.doi.org/10.1128/AAC.50.2.658-666.2006.
10. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220. http://dx.doi.org/10.2165/00003088-200544020-00006.
11. Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, Caceres M, Kartsonis N, Waskin H, Robertson MN. 2014. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob. Agents Chemother. 58:3610-3617. http://dx.doi.org/10.1128/AAC.02686-13.
12. Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. 2012. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single-and multiple-dose pharmacokinetics and safety in healthy volunteers. J. Antimicrob. Chemother. 67:2725-2730. http://dx.doi.org/10.1093/jac/dks268.
13. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865. http://dx.doi.org/10.1128/AAC.00931-09.
14. Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW. 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203:1324-1332. http://dx.doi.org/10.1093/infdis/jir023.
15. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. 2013. Posaconazole pharmacodynamic target determination against wild-type and cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 57:579-585. http://dx.doi.org/10.1128/AAC.01279-12.
16. Luo G, Gebremariam T, Lee H, French SW, Wiederhold NP, Patterson TF, Filler SG, Ibrahim AS. 2013. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob. Agents Chemother. 57:3340-3347. http://dx.doi.org/10.1128/AAC.00313-13.
17. Spreghini E, Orlando F, Giannini D, Barchiesi F. 2010. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. J. Antimicrob. Chemother. 65:2158-2163. http://dx.doi.org/10.1093/jac/dkq276.
18. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47:3647-3650. http://dx.doi.org/10.1128/AAC.47.11.3647-3650.2003.
19. Wiederhold NP, Tam VH, Chi JD, Prince RA, Kontoyiannis DP, Lewis RE. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:469-473. http://dx.doi.org/10.1128/AAC.50.2.469-473.2006.
20. Lewis RE, Leventakos K, Liao G, Kontoyiannis DP. 2011. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob. Agents Chemother. 55:3584-3587. http://dx.doi.org/10.1128/AAC.01812-10.
21. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. 2007. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 51:1253-1258. http://dx.doi.org/10.1128/AAC.01449-06.
22. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. 2010. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob. Agents Chemother. 54:1298-1304. http://dx.doi.org/10.1128/AAC.01222-09.
23. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M39-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
24. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471. http://dx.doi.org/10.1086/424465.
25. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards JE, Jr, Douglas CM. 2005. Caspofungin inhibits rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727. http://dx.doi.org/10.1128/AAC.49.2.721-727.2005.
26. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D. 2004. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48:137-142. http://dx.doi.org/10.1128/AAC.48.1.137-142.2004.
27. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, Kontoyiannis DP, Walsh TJ. 2012. Combination therapy for mucormycosis: why, what, and how? Clin. Infect. Dis. 54(Suppl. 1):S73-S78.
28. European Committee on Antimicrobial Susceptibility Testing. 2012. Posaconazole and Aspergillus spp.: rationale for the EUCAST clinical breakpoints v 1.0. http://www.eucast.org/clinical-breakpoints/.
29. Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE, Jr, Spellberg BJ. 2007. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Invest. 117:2649-2657. http://dx.doi.org/10.1172/JCI32338.
30. Ibrahim AS, Spellberg B, Edwards J, Jr. 2008. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr. Opin. Infect. Dis. 21:620-625. http://dx.doi.org/10.1097/QCO.0b013e3283165fd1.
31. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, Brass EP. 2012. The deferasirox-Ambisome therapy for mucormycosis (defeat mucor) study: a randomized, doubleblinded, placebo-controlled trial. J. Antimicrob. Chemother. 67:715-722. http://dx.doi.org/10.1093/jac/dkr375.
32. Donnelly JP, Lahav M. 2012. Deferasirox as adjunctive therapy for mucormycosis. J. Antimicrob. Chemother. 67:519-520. http://dx.doi.org/10.1093/jac/dkr540.
33. Merck & Co, Inc. 2014. Noxafil prescribing information (suspension, delayed release tablet, and intravenous formulation). Merck & Co, Inc., Whitehouse Station, NJ. \